PT-141
Also known as: Bremelanotide, Vyleesi
PT-141 (Bremelanotide) is a melanocortin receptor agonist that works on the central nervous system to enhance sexual arousal and desire. It is FDA-approved for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.
Beginner Basics
Plain-English guide to PT-141
What it does
This peptide signals your brain to increase sexual desire and arousal by working on nerve pathways rather than blood vessels. Researchers use it to help both men and women who experience low sexual interest.
Typical dose
1-2 mg injected under the skin or sprayed in the nose, taken as needed about 45 minutes before sexual activity.
When to inject
Take it 45-60 minutes before you plan to be intimate, so it has time to work.
Storage
Keep the powder in the refrigerator before mixing. After you mix it with liquid, store it in the fridge and use it within the timeframe specified by your supplier.
First-timer tip
Start with the lower dose (1 mg) your first time since nausea and facial flushing are common side effects when beginning-these typically fade with repeated use.
On This Page
Research Status
FDA-approved for female hypoactive sexual desire disorder (Vyleesi)
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in approximately 40% of users, typically mild and transient. Usually resolves within 30-60 minutes. Taking PT-141 with food or on a partially full stomach may reduce incidence. Antiemetics (e.g., ginger, ondansetron) can be used if severe.
Redness and warmth in the face and neck occur in 30-50% of users. Usually mild, self-resolving within 1-2 hours. Related to MC4R activation and increased blood flow. Not medically concerning but may be socially noticeable.
Reported in 5-15% of users. Usually mild and resolves within a few hours. May be related to vascular changes or increased intracranial pressure. Standard analgesics (acetaminophen, ibuprofen) are effective if needed.
Increased melanin production can occur due to MC4R activation on melanocytes. Darkening of existing moles or development of new pigmented lesions has been reported. Dermatological monitoring is recommended, especially in users with a history of melanoma or atypical moles. This effect is reversible upon discontinuation.
Redness, itching, or mild swelling at the injection site can occur. Usually resolves within 24 hours. Proper site rotation and sterile injection technique minimize risk. Ice application can reduce inflammation if needed.
Small increases in systolic and diastolic blood pressure have been observed in clinical trials. More common in users with baseline hypertension. Blood pressure monitoring is recommended, especially in those with cardiovascular risk factors. Contraindicated in uncontrolled hypertension.
Unexpected or unwanted erections may occur, particularly in the hours following injection. This is an expected pharmacological effect but can be socially inconvenient. Timing of injection relative to planned sexual activity can help manage this.
Reported in <5% of users. May be related to blood pressure changes or vasodilation. Avoid driving or operating machinery if dizziness occurs. Usually resolves within 1-2 hours.
Slight increases in heart rate have been observed. Usually mild and transient. Users with cardiac arrhythmias or heart disease should use with caution and medical supervision.
While nausea is common, actual vomiting is rare (<5%). If vomiting occurs, discontinue use and seek medical advice. Dehydration risk if vomiting is severe or repeated.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 1-2 mg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 1025.2 g/mol |
| Half-life | Approximately 26 minutes (plasma half-life); duration of effect 2-3 hours |
| Sequence | Members only |
PT-141 (bremelanotide) is a melanocortin-4 receptor (MC4R) agonist that acts on the central nervous system to enhance sexual arousal and desire in both men and women. By activating MC4R signaling pathways in the hypothalamus and other brain regions involved in sexual function, PT-141 increases dopamine and other neurotransmitters that promote sexual motivation and arousal, independent of hormonal status.
Track your PT-141 research
Free account. No credit card required.
Recent Research
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. PT-141 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.